TY - JOUR
T1 - Precursor B-cell lymphoblastic lymphoma
T2 - A study of nine cases lacking blood and bone marrow involvement and review of the literature
AU - Maitra, Anirban
AU - McKenna, Robert W.
AU - Weinberg, Arthur G.
AU - Schneider, Nancy R.
AU - Kroft, Steven H.
PY - 2001
Y1 - 2001
N2 - We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. Of these, 64% were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74% of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.
AB - We describe 9 cases of precursor B-cell lymphoblastic lymphoma (LYL) without evidence of marrow or blood involvement. Four patients had superficial nodal disease, 2 cutaneous involvement, and 1 each ovarian, retroperitoneal, or tonsillar primary tumor. Six patients had limited disease; 3 patients were stage III. Immunophenotyping revealed a terminal deoxynucleotidyl transferase (TdT)-positive, immature B-cell population with variable expression of CD10, CD20, and CD45. All patients are in complete clinical remission (median follow-up, 14 months). A literature review yielded 105 patients with a diagnosis of precursor B-cell LYL based on less than 25% marrow involvement. Of these, 64% were younger than 18 years. Skin, lymph nodes, and bone were the most common sites of disease. Mediastinal involvement was uncommon. TdT, CDI9, CD79a, CD10, and HLA-DR were the most frequently expressed antigens, while CD45 and CD20 were expressed in only two thirds of the cases. Cytogenetic analysis showed additional 21q material as a recurring karyotypic abnormality. At a median follow-up of 26 months, 74% of patients were alive; the median survival was 19 months for patients dying of disease. Comparison with precursor B-cell acute lymphoblastic leukemia showed several overlapping features, although distinct differences were identified.
KW - Acute lymphoblastic leukemia
KW - Lymphoblastic lymphoma
KW - Precursor B-cell lymphoma, Precursor B-cell ALL
UR - http://www.scopus.com/inward/record.url?scp=0035000322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035000322&partnerID=8YFLogxK
U2 - 10.1309/Q5GV-3K00-WAC6-BBUB
DO - 10.1309/Q5GV-3K00-WAC6-BBUB
M3 - Article
C2 - 11392884
AN - SCOPUS:0035000322
SN - 0002-9173
VL - 115
SP - 868
EP - 875
JO - American journal of clinical pathology
JF - American journal of clinical pathology
IS - 6
ER -